科研动态期刊摘要

[评论] 依非诺肽:迈向MASH精准治疗的一步?

The Lancet Online First · 2026-11-10

摘要

代谢功能障碍相关脂肪性肝炎(MASH)在不同人群中的全球影响显著。MASH肝硬化已成为肝移植的主要适应证和肝细胞癌的主要驱动因素。晚期MASH纤维化与全因死亡率增加及肝外恶性肿瘤风险增加近两倍相关。1

English
[Comment] Efinopegdutide: a step towards precision in MASH therapy?

The global impact of metabolic dysfunction-associated steatohepatitis (MASH) across diverse populations is significant. MASH cirrhosis has become a leading indication for liver transplantation and a primary driver of hepatocellular carcinoma. Advanced MASH fibrosis is associated with increased all-cause mortality and a nearly two-times increased risk of extrahepatic malignancies.1

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界